Fresenius SE & Co. KGaA (FSNUY) Stock

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.

Fresenius SE & Co. KGaA is headquartered in DE.

Fresenius SE & Co. KGaA (FSNUY) stock trades at $13.57 with a market capitalization of $122.29B. The stock is valued at a price-to-earnings (P/E) ratio of 17.69, price-to-book of 1.33, price-to-sales of 1.15. Over the past 52 weeks the stock has ranged between $10.33 and $33.93, and currently trades 60.0% below its 52-week high. It pays a dividend yielding 2.21%.

On profitability, Fresenius SE & Co. KGaA generates a return on equity (ROE) of 7.76%, return on capital employed of 6.63%, an operating margin of 9.45%, a net profit margin of 6.38%.

In its most recent fiscal year, Fresenius SE & Co. KGaA reported annual revenue of $22.0B, net profit of $1.2B, revenue has compounded at -9.5% a year over the last five years, profit at -6.6% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.60, a current ratio of 1.27, total assets of $41.4B, $1.6B in cash and equivalents.

FSNUY has an average daily trading volume of 237,974 shares, a beta of 0.83.

Official website: www.fresenius.com